

Urogen N.A., Inc. Retains The Investor Relations Group of New York

Monday October 30, 2:30 pm ET - BusinessWire

BURLINGAME, Calif.--(BUSINESS WIRE)--Urogen N.A., Inc. has retained The Investor Relations Group, Inc. (IRG), a full-service investor relations firm, to serve as its new investor relations and corporate communications agency.

"Urogen has an extensive product pipeline for urological disorders. The Investor Relations Group will ensure our developments reach investors," said William J. Garner, President and Chief Executive Officer of Urogen. "Simultaneously, IRG will play an integral role in communicating our progress to the pharmaceutical community and the individuals in pain from urological disorders who may want to watch for their ultimate commercialization."

IRG will strive to increase investor and industry awareness of Urogen and its products within the United States and world markets by introducing the Company and its Management to pre-qualified fund managers, analysts and the media-at-large.

About Urogen N.A., Inc.

Urogen N.A., Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urogen has five programs in development that are either in or positioned to enter Phase 2 clinical trials. The pipeline includes U101, for the treatment of Chronic Pelvic Pain (CPP); U102, targeting symptoms of CPP secondary to pelvic irradiation; U103, targeting dyspareunia; U301, targeting acute urethral discomfort; and U302, targeting urethritis. For further information, please visit the Company's website at www.urogen.com.

About The Investor Relations Group

The Investor Relations Group, Inc., (IRG) founded in 1996, represents select publicly traded companies, with a unique specialization for assisting those in the small-cap sector. IRG arranges one-on-one meetings for its portfolio companies with pre-qualified money managers handling investment portfolios that range from \$10 million to \$10 billion+ selected from its proprietary contact base of over 70,000 qualified fund managers who have an investing history in small cap stocks. IRG's corporate communications services include writing all press releases and shareholder communications and serving as primary contact for the investing community, with the focus of building awareness of its companies within the financial and trade media, as well as the public at large. For further information, please visit the company's website at www.investorrelationsgroup.com.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

SOURCE: Urogen N.A., Inc.

Urogen N.A., Inc.
Martin Shmagin
Chief Financial Officer

Phone: 415-971-1080
www.urigen.com

The Investor Relations Group
Investor Relations: Katrine Winther-Olesen
Media Contacts: Janet Vasquez / Lynn Granito
Phone: 212-825-3210